Articles - Gastric Cancer A specially curated list of peer-reviewed articles discussing the latest advancements in the diagnosis and treatment of patients with Gastric Cancer. Filter by TopicAdenocarcinomaAdenocarcinomas of the Esophagogastric JunctionASGE GuidelinesAZD8186Barrett's and AdenocarcinomaBiomarkersCancer-Associated FibroblastsCarcinoma EsophagusCD8+ T-Cell InfiltrationChemoimmunotherapyChemotherapyCixutumumabClinical OutcomeClinical PracticeClinical TrialComprehensive TherapyCytoreductive SurgeryDefinitive ChemoradiotherapyDiagnosisDocetaxelEndoscopic Submucosal DissectionEndoscopy Upper GI TractEpstein-Barr VirusEsophageal CancerEsophageal NeoplasmEsophageal Squamous Cell CancerEsophagogastric AdenocarcinomaEsophagogastric CancerEsophagogastric JunctionEthnic MinorityGastrectomyGastric AdenocarcinomaGastric CancerGastric or Gastroesophageal Junction CancerGastro-Oesophageal Junction AdenocarcinomaGastroesophageal JunctionGastroesophageal Junction AdenocarcinomaGastroesophageal Junction CarcinomaGastroesophageal Junction TumorGuidelinesHER2-Positive Esophagogastric CancerHER2-Positive Gastric CancerHeterogeneityHuman Epidermal Growth Factor Receptor 2 (HER-2)Hyperthermic Intraperitoneal ChemotherapyImagingImmune Checkpoint BlockadeImmunotherapyInsulin-Like Growth Factor-1 ReceptorIntratumoral MicrobiotaLocally Advanced Gastric CancerMalnutritionManagementMaximum Tolerated DoseMean Platelet VolumeMicroenvironmentMicrosatellite Instability (MSI)Minimally Invasive EsophagectomyMultimodality TherapyNeoadjuvant ChemoradiotherapyNeoadjuvant RadiationNeoadjuvant TreatmentNivolumabOesophageal AdenocarcinomaOligometastatic Disease StateOxaliplatinPaclitaxelPalliative CarePalliative ChemotherapyPancreatic Ductal AdenocarcinomaPathologic ResponsePatient StratificationPD-1 InhibitorsPembrolizumabPeritoneal MetastasisPhase 3 TrialPlasma Circulating Tumor DNAPlatelet CountPost Operative ComplicationsPreoperative ChemoradiotherapyPreoperative ChemotherapyProgrammed Cell Death Ligand 1 (PD-L1)Progression-Free SurvivalProtein UbiquitinationRamucirumabRandomised Controlled TrialResponse PredictionS-1 Plus SurgerySignet Ring HistologyStereotactic Body RadiotherapyStomach NeoplasmsSupportive OncologySurgerySurvival BenefitSymptom BurdenTACETargeted TherapyThoracoscopic and Laparoscopic EsophagectomyTissue-Based Predictive MarkersTNM StagingToxicityTrastuzumabTrastuzumab DeruxtecanTreatmentTumor ImmunosuppressionTumor MicroenvironmentTumor Mutational BurdenVascular Endothelial Growth Factor Receptor 2 (VEGFR-2)Zolbetuximab Efficacy and safety of camrelizumab combined with oxaliplatin and S-1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: A phase II, single-arm study READ MORE Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023 READ MORE First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial READ MORE Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials READ MORE Who Should Receive Immunotherapy for Advanced Gastroesophageal Cancer? READ MORE Outcomes after Surgical Treatment of Oesophagogastric Cancer with Synchronous Liver Metastases: A Multicentre Retrospective Cohort Study READ MORE Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol READ MORE First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study READ MORE Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma: The Phase 2 RAP (AIO-STO-0218) Nonrandomized Controlled Trial READ MORE Controversies in upper GI oncology: MSI-H in gastroesophageal adenocarcinoma READ MORE Tumor mutation load better predicts the prognosis of patients treated with immune checkpoint inhibitors in upper gastrointestinal cancers: A systematic review and meta-analysis READ MORE Low-Dose Radiation Yields Lower Rates of Pathologic Response in Esophageal Cancer Patients READ MORE The Multidisciplinary Approach and Surgical Management of GE Junction Adenocarcinoma READ MORE Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial READ MORE Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial READ MORE Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial READ MORE NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma READ MORE Management of Microsatellite Instability High (MSI-H) Gastroesophageal Adenocarcinoma READ MORE NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma READ MORE Multimodal Therapy Versus Primary Surgery for Gastric and Gastroesophageal Junction Diffuse Type Carcinoma, with a Focus on Signet Ring Cell Carcinoma: A Nationwide Study READ MORE Immunotherapy in Esophagogastric Cancer: Treatment Landscape, Challenges, and New Directions READ MORE Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021) READ MORE Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study READ MORE Untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with the progression of gastroesophageal cancer READ MORE Population-based evaluation of disparities in stomach cancer by nativity among Asian and Hispanic populations in California, 2011–2015 READ MORE Decreased expression of TFF2 and decreased αGlcNAc glycosylation are malignant biomarkers of pyloric gland adenoma of the duodenum READ MORE Role of F-box proteins in human upper gastrointestinal tumors READ MORE Comparative efficacy and tolerability of first-line treatments for untreated, HER2-negative, advanced gastric cancer: systematic review and network meta-analysis READ MORE Claudin18.2 in Advanced Gastric Cancer READ MORE Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction CancerThe ORIENT-16 Randomized Clinical Trial READ MORE Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial READ MORE Recent advances for treatment of upper gastrointestinal malignancy READ MORE LINE-1 hypomethylation, increased retrotransposition and tumor-specific insertion in upper gastrointestinal cancer READ MORE Energy Expenditure in Upper Gastrointestinal Cancers: a Scoping Review READ MORE Current state of the art: immunotherapy in esophageal cancer and gastroesophageal junction cancer READ MORE Delayed Surgical Intervention After Chemoradiotherapy in Esophageal Cancer READ MORE Multicenter phase I dose escalation and expansion study of pyrotinib in combination with camrelizumab and chemotherapy as first-line treatment for HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma READ MORE Retooling treatment in oligometastatic oesophageal cancer READ MORE Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial READ MORE Role of Immunotherapy in Gastroesophageal Cancers—Advances, Challenges and Future Strategies READ MORE Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study READ MORE Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial READ MORE Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study READ MORE Patient choice of surgery or surveillance following a clinical complete response to neoadjuvant chemoradiotherapy for oesophageal carcinoma READ MORE The Society of Thoracic Surgeons/American Society for Radiation Oncology Updated Clinical Practice Guidelines on Multimodality Therapy for Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction READ MORE Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry READ MORE Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial READ MORE Total neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma READ MORE DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery plus postoperative S-1: a sub-analysis of the phase 3 PRODIGY trial READ MORE Independent Stage Classification for Gastroesophageal Junction Adenocarcinoma READ MORE Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract READ MORE Great Debate: Chemoradiation Should be Added to Chemotherapy as a Neoadjuvant Treatment Strategy for Resectable Gastric Adenocarcinoma READ MORE Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial READ MORE The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy READ MORE Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma READ MORE High symptom burden in patients undergoing gastrectomy for cancer READ MORE READ MORE Potential Predictive Immune and Metabolic Biomarkers of Tumor Microenvironment Regarding Pathological and Clinical Response in Esophageal Cancer After Neoadjuvant Chemoradiotherapy: A Systematic Review READ MORE Early prediction of response to palliative chemotherapy in patients with stage-IV gastric and esophageal cancer READ MORE Three staged minimally invasive esophagectomy with end-to-end esophago-gastric anastomosis for thoracic esophageal cancers: An experience from a Low Middle-Income Country READ MORE Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: Analysis of Number Needed To Treat and Number Needed To Harm READ MORE Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma READ MORE Umbrella systematic review of potential quality indicators for the detection of dysplasia and cancer at upper gastrointestinal endoscopy READ MORE Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer READ MORE Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer READ MORE Clinical and Molecular Characteristics of Early-Onset versus Average-Onset Esophagogastric Cancer READ MORE Antireflux Surgery Versus Antireflux Medication and Risk of Esophageal Adenocarcinoma in Patients With Barrett’s Esophagus READ MORE Platelets as a prognostic factor for patients with adenocarcinoma of the gastroesophageal junction READ MORE Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study READ MORE PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer READ MORE Late Toxicity and Health-Related Quality of Life Following Definitive Chemoradiotherapy for Esophageal Cancer: A Systematic Review and Meta-analysis READ MORE Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial READ MORE American Society for Gastrointestinal Endoscopy guideline on endoscopic submucosal dissection for the management of early esophageal and gastric cancers: summary and recommendations READ MORE Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers READ MORE Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer READ MORE Key Genetic Determinants Driving Esophageal Squamous Cell Carcinoma Initiation and Immune Evasion READ MORE AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20) READ MORE Human epidermal growth factor receptor 2-positive metastatic gastric cancer in complete sustained remission with trastuzumab READ MORE Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline READ MORE HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial READ MORE Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials READ MORE Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up READ MORE Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy READ MORE Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data READ MORE The New Era of Immunotherapy in Gastric Cancer READ MORE The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer READ MORE Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study READ MORE First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial READ MORE Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer READ MORE Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials READ MORE Real-life use of ramucirumab in gastric cancer in Spain: the RAMIS study READ MORE Epstein–Barr virus-associated gastric cancer: A distinct subtype READ MORE Gastric cancer READ MORE Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer READ MORE First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial READ MORE Biomarkers of gastric cancer: Current topics and future perspective READ MORE Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial READ MORE Facebook Twitter Linkedin
